Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Intestinal microbiota mediate toxicity of irinotecan (CPT-11) cancer therapies and cause systemic infection after CPT-11-induced loss of barrier function. The intestinal microbiota and their functions are thus potential targets for treatment to mitigate CPT-11 toxicity. However, microbiota changes during CPT-11 therapy remain poorly described. This study analysed changes in intestinal microbiota induced by CPT-11 chemotherapy. Qualitative and quantitative taxonomic analyses, and functional analyses were combined to characterize intestinal microbiota during CPT-11-based chemotherapy, and in presence or absence of oral glutamine, a treatment known to reduce CPT-11 toxicity. In the first set of experiments tumour-bearing rats received a dose-intensive CPT-11 regimen (125 mg kg(-1)×3 days), with or without oral glutamine bolus (0.75 g kg(-1)). In a subsequent more clinically-oriented chemotherapy regimen, rats received two cycles of CPT-11 (50 mg kg(-1)) followed by 5-flurouracil (50 mg kg(-1)). The analysis of fecal samples over time demonstrated that tumours changed the composition of intestinal microbiota, increasing the abundance of clostrridial clusters I, XI, and Enterobacteriaceae. CPT-11 chemotherapy increased cecal Clostridium cluster XI and Enterobacteriaceae, particularly after the dose-intensive therapy. Glutamine treatment prevented the reduced abundance of major bacterial groups after CPT-11 administration; i.e. total bacteria, Clostridium cluster VI, and the Bacteroides-group. Virulence factor/toxin genes of pathogenic Escherichia coli and Clostridium difficile were not detected in the cecal microbiota. In conclusion, both colon cancer implantation and CPT-11-based chemotherapies disrupted the intestinal microbiota. Oral glutamine partially mitigated CPT-11 toxicity and induced temporary changes of the intestinal microbiota.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Benson, A. K., Kelly, S. A., Legge, R., Ma, F., Low, S. J., Kim, J., Zhang, M., Oh, P. L., Nehrenberg, D., Hua, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007028107 · Cited by 1,314
Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., & Zhao, L. (2012) · The ISME Journal · doi:10.1038/ismej.2011.109 · Cited by 1,287
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699 · cited 1×
“Intestinal microbiota disruption or dysbiosis is associated with various mucositis-related diseases, including inflammatory bowel disease [24], irritable bowel syndrome [25], and colorectal cancer [26].”
BackgroundImmune Responses to the Microbiota at the Intestinal Mucosal Surface
Duerkop, B. A., Vaishnava, S., & Hooper, L. V. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.009 · Cited by 424
Biostructure of Fecal Microbiota in Healthy Subjects and Patients With Chronic Idiopathic Diarrhea
Swidsinski, A., Loening–Baucke, V., Verstraelen, H., Osowska, S., & Doerffel, Y. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.017 · Cited by 178 · cited 1×
“difficile when human or rodent normal microbiota are severely altered in chemotherapies using various drugs [2,3], radiotherapy [30,31], inflammatory bowel disease [32,33], chronic idiopathic diarrhea [34], or antibiotic treatment [35].”
Background
Cited by
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
“The effect of CPT-11 on the intestinal microbiota composition has been explored in rats 43 .”
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients
Boleij, A., Hechenbleikner, E. M., Goodwin, A. C., Badani, R., Stein, E. M., Lazarev, M. G., Ellis, B., Carroll, K. C., Albesiano, E., Wick, E. C., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu787 · Cited by 625
Human Gut Microbiota and Gastrointestinal Cancer
Meng, C., Bai, C., Brown, T. D., Hood, L. E., & Tian, Q. (2018) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.06.002 · Cited by 467
Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., Le Vacon, F., & de La Cochetière, M. F. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12878 · Cited by 425
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
“Irinotecan can also alter the composition of the intestinal microbiome in rats, although it is unclear how well this aligns with the toxicity of this treatment (Lin et al., 2012; Alexander et al., 2017).”
BackgroundPharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Panebianco, C., Andriulli, A., & Pazienza, V. (2018) · Microbiome · doi:10.1186/s40168-018-0483-7 · Cited by 298
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Chrysostomou, D., Roberts, L. A., Marchesi, J. R., & Kinross, J. M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.10.018 · Cited by 283
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Hou, H., Chen, D., Zhang, K., Zhang, W., Liu, T., Wang, S., Dai, X., Wang, B., Zhong, W., & Cao, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.11.027 · Cited by 263
Bindels, L. B., Neyrinck, A. M., Claus, S. P., Le Roy, C. I., Grangette, C., Pot, B., Martinez, I., Walter, J., Cani, P. D., & Delzenne, N. M. (2016) · The ISME Journal · doi:10.1038/ismej.2015.209 · Cited by 209
“Some of these changes have also been observed in the previous studies (Lin et al., 2012; Bindels et al., 2012a), and have been reported as a sign of reduced colonization resistance (Lawley and Walker, 2013).”
Gut Microbiota Shapes the Efficiency of Cancer Therapy
Ma, W., Mao, Q., Xia, W., Dong, G., Yu, C., & Jiang, F. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01050 · Cited by 192
“Clostridium species decrease from the initial time of irinotecan therapy to recovery on day 7, but the abundance of Bifidobacterium and Lactobacillus species is persistently reduced (Lin et al., 2012).”
BackgroundGut microbiome and anticancer immune response: really hot Sh*t!
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123
Dashnyam, P., Mudududdla, R., Hsieh, T.-J., Lin, T.-C., Lin, H.-Y., Chen, P.-Y., Hsu, C.-Y., & Lin, C.-H. (2018) · Scientific Reports · doi:10.1038/s41598-018-34678-z · Cited by 108
From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation
Bajic, J. E., Johnston, I. N., Howarth, G. S., & Hutchinson, M. R. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00104 · Cited by 100
Metadata
- Authors
- Lin, X. B., Dieleman, L. A., Ketabi, A., Bibova, I., Sawyer, M. B., Xue, H., Field, C. J., Baracos, V. E., & Gänzle, M. G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-26
- Volume
- 7
- Issue
- 7
- Pages
- e39764
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1992895388
- Cited by
- 159
- References
- 6
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.